Drug Profile
Birch pollen allergoid - Allergopharma
Alternative Names: Allergovit Birch; Birch pollen allergy immunotherapy - AllergopharmaLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Allergopharma
- Class Allergens; Peptide vaccines; Peptides; Skin disorder therapies; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Seasonal allergic rhinitis
Most Recent Events
- 28 Jun 2023 Phase-II clinical trials in Seasonal allergic rhinitis (In children, In adults, In adolescents) in Poland (SC)
- 29 Mar 2023 Allergopharma completes a phase II trial for Seasonal allergic rhinitis in Germany and Poland (SC) (EudraCT2021-002317-34)
- 30 Mar 2017 Allergopharma completes a phase II trial for Seasonal allergic rhinitis in Germany (SC) (EudraCT2015-005400-28)